Taysha Gene Therapies, Inc., a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN1 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 foe the treatment of for SLC13A5 Deficiency; and TSHA-101 for the treatment of GM2 gangliosidosis. Taysha Gene Therapies, Inc. has a strategic partnership with The University of Texas Southwestern Medical Center to develop and commercialize transformative gene therapy treatments. The company was incorporated in 2019 and is based in Dallas, Texas.

Taysha Gene Therapies, Inc.

Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system (CNS)/ocular diseases. Its marketed products include ONPATTRO (patisiran), a lipid complex injection for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria (AHP); and OXLUMO (lumasiran) for the treatment of primary hyperoxaluria type 1 (PH1). In addition, the company is developing givosiran for the treatment of adolescent patients with AHP; patisiran for the treatment of transthyretin amyloidosis, or ATTR amyloidosis, with cardiomyopathy; cemdisiran to treat complement-mediated diseases; ALN-AAT02 for the treatment of AAT deficiency-associated liver disease; ALN-HBV02 to treat chronic HBV infection; Zilebesiran to treat hypertension; and ALN-HSD to treat NASH. Further, it offers Fitusiran for the treatment of hemophilia and rare bleeding disorders, Inclisiran to treat hypercholesterolemia, lumasiran for the treatment of advanced PH1 and recurrent renal stones, and vutrisiran for the treatment of ATTR amyloidosis, which is in phase 3 clinical trial. Alnylam Pharmaceuticals, Inc. has strategic collaborations with Regeneron Pharmaceuticals, Inc. to discover, develop, and commercialize RNAi therapeutics for a range of diseases by addressing therapeutic targets expressed in the eye and CNS; and Sanofi Genzyme to discover, develop, and commercialize RNAi therapeutics. It also has license and collaboration agreements with Novartis AG; Vir Biotechnology, Inc.; Dicerna Pharmaceuticals, Inc.; Ionis Pharmaceuticals, Inc.; and PeptiDream, Inc. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts.

Alnylam Pharmaceuticals, Inc.

Chardan NexTech Acquisition 2 Corp. does not have significant operations. The company focuses on effecting a merger, share exchange, asset acquisition, stock purchase, recapitalization, reorganization, or other similar business combination with one or more businesses. It intends to focus on businesses in the financial services, healthcare, real estate services, technology, and software industries. The company was incorporated in 2020 and is headquartered in New York, New York.

Chardan NexTech Acquisition 2 Corp.

Taysha GTx focuses on developing gene therapies for diseases of the central nervous system caused by the mutation of a single gene, known as monogenic diseases.

Metric
Company Name	Taysha Gene Therapies, Inc.	Alnylam Pharmaceuticals, Inc.	Chardan NexTech Acquisition 2 Corp.
Symbol	TSHA	ALNY	CNTQ
MSH ID	COM:TAYSHAGTX	COM:ALNYLAM	COM:CHARDAN
Market	STOCKS	STOCKS	STOCKS
Sector	Healthcare	Healthcare	Financial Services
Industry	Biotechnology	Biotechnology	Shell Companies
Country	US	US	US
Stage
Employee Count	52	2.10K
Website	tayshagtx.com	alnylam.com	chardan.com
LinkedIn
Founders

Metric
Market Cap	455.12M	32.60B	605.82M
Enterprise Value
Monthly Web Traffic		55.97K	2.99K
Web Traffic Growth		0.89	10.82
Valuation
Raised Capital		900M

Metric
Revenue	15.45M	1.83B	64.39M
Revenue (LTM)
Revenue (NTM)
Gross Profit	15.45M	1.52B	15.45M
EBITDA	-72.44M	-228.12M	-26.19M
Operating Income	-72.44M	-282.18M	-27.43M
Net Income	-111.57M	-440.24M	-13.82M
EPS	-0.00	-3.52	-0.26
Diluted EPS	-0.00	-3.52	-0.26
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin	0.92	0.87	0.25
Operating Profit Margin	-4.66	0.04	-0.40
EBITDA Margin	-4.69	-0.12	-0.41
Net Profit Margin	-7.38	-0.03	-0.05
Return on Equity	17.38	1.67	-0.10
Return on Assets	-0.43	-0.02	-0.04
Return on Capital Employed	-0.31	0.03	-0.52

COM:TAYSHAGTX

Taysha GTx

Last Close

2.18

22/11 21:00

Market Cap

455.12M

Beta: -

Volume Today

9.79M

Avg: -

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio	-0.89	-42.10	-7.90
P/B Ratio	-3.99	-129.43
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio	52.71	16.84	1.29
EV Multiple	-5.55	326.32	0.71

Metric
Days Sales Outstanding		68.92
Days Payables Outstanding		97.72
Days Inventory Outstanding		128.53	289.18
Operating Cycle		187.09	298.47
Cash Conversion Cycle	-820.81	104.98	228.89
Asset Turnover	0.09	0.58	0.90

Metric
Operating Cash Flow	-73.02M	104.16M	-17.71M
Free Cash Flow	-76.89M	41.95M	-24.59M
Cash Flow to Debt	-0.72	0.15	-0.32
Operating Cash Flow/Sales	-2.97	0.16	-0.27
Free Cash Flow Yield	-0.18	-0.00	0.03

Metric
Cash & Equivalents	143.94M	812.69M	12.71M
Accounts Receivable		-87.94M	-309K
Inventory		89.15M	38.78M
Goodwill
Debt to Capitalization	5.88	1.20	0.90
Debt to Assets	0.30	0.34
Current Ratio	0.95	3.14
Quick Ratio	5.22	3.07	0.43

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue	0.70	0.13
R&D to Revenue	4.04	0.58	0.03
SG&A to Revenue	2.14	0.35	0.49